摘要
伊马替尼是治疗慢性髓性白血病(CML)的一线药物,具有选择性高、疗效显著等特点。但临床上仍有30%~40%的患者服用伊马替尼后未获得理想的治疗效果。随着精准用药概念的提出,伊马替尼新型治疗模式——个体化用药逐渐受到重视。本文就采用伊马替尼治疗的CML患者血药浓度和相关基因多态性与临床疗效关系的研究进展做一综述,以期为临床采用伊马替尼治疗CML患者的个体化用药方案提供参考依据。
Imatinib is used in the first-line treatment for chronic myelocytic leukemia(CML).It has high selectivity and efficacy.However,30%to 40%CML patients exhibit no response and/or intolerance to imatinib.With introduction of the concept of precision medication,personalized medicine,a new treatment mode of imatinib,has gradually attracted more and more attention.Therefore,we focused on the research progress of the effects of trough concentration and gene polymorphism on imatinib response in chronic myeloid leukemia,so as to provide references for imatinib clinical individualized treatment.
作者
黄玲玲
姚媛
沈成银
陈美玲
黄雄文
黄峰
王君萍
高杉
HUANG Lingling;YAO Yuan;SHEN Chengyin;CHEN Meiling;HUANG Xiongwen;HUANG Feng;WANG Junping;GAO Shan(Department of Pharmacy,Cancer Hospital,Chinese Academy of Sciences,Hefei,Anhui,230031,China;Anhui Province Key Laboratory of Medical Physics and Technology,Center of Medical Physics and Technology,Hefei Institutes of Physical Science,Chinese Academy of Sciences,Hefei,Anhui,230031,China;Center of Medical Physics and Technology,Hefei Institutes of Physical Science,Chinese Academy of Sciences,Hefei,Anhui,230031,China;Department of Pharmacology,Anhui Medical University,Hefei,Anhui,230032,China)
出处
《肿瘤药学》
CAS
2019年第4期544-549,571,共7页
Anti-Tumor Pharmacy
基金
中国科学院合肥肿瘤医院院长基金项目（YZJJ2019A05）
关键词
伊马替尼
慢性髓性白血病
基因多态性
血浆谷浓度
Imatinib
Chronic myeloid leukemia
Gene polymorphism
Plasma trough concentration(C0)
